Nektar Therapeutics

NasdaqCM:NKTR Stock Report

Market Cap: US$258.2m

Nektar Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

Nektar Therapeutics has a total shareholder equity of $48.9M and total debt of $97.8M, which brings its debt-to-equity ratio to 200.1%. Its total assets and total liabilities are $308.0M and $259.1M respectively.

Key information

200.1%

Debt to equity ratio

US$97.83m

Debt

Interest coverage ration/a
CashUS$244.50m
EquityUS$48.88m
Total liabilitiesUS$259.08m
Total assetsUS$307.97m

Recent financial health updates

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nov 06
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Apr 24
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Recent updates

Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Oct 18
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

Jun 19
Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31
Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nov 06
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Apr 24
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11
We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline

Apr 04

Financial Position Analysis

Short Term Liabilities: NKTR's short term assets ($286.5M) exceed its short term liabilities ($67.6M).

Long Term Liabilities: NKTR's short term assets ($286.5M) exceed its long term liabilities ($191.5M).

Debt to Equity History and Analysis

Debt Level: NKTR has more cash than its total debt.

Reducing Debt: NKTR's debt to equity ratio has increased from 21.6% to 200.1% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NKTR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NKTR has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 22.2% each year.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y